Pangea Bio

🚨 We’re Hiring! 🚨 At Pangea Bio, we’re looking for an experienced R&D Project Manager, Nonclinical Development, to join our team for a 1-year maternity leave cover. This is a fantastic opportunity to work on groundbreaking CNS disease research in a fast-paced biotech setting and help launch and run our Phase 1 clinical study. If you have experience in clinical formulation development, regulatory writing and nonclinical project management, we’d love to hear from you! 📌 Learn more & apply here: https://lnkd.in/e9BJ9jGR Know someone who would be a great fit? Tag them or share this post! #PangeaBio #Hiring #BiotechJobs #StartupJobs #NonclinicalDevelopment #CNS #Biotech

We are thrilled to share that our CITO, Prof Andreas Bender, has accepted a Professorship for Machine Learning in Medicine at the College of Medicine and Health Sciences (CMHS) at Khalifa University in Abu Dhabi! After nearly 15 years as a Professor at the University of Cambridge, Andreas will continue to advance his research in AI-enabled drug discovery, driving innovation in this rapidly evolving field—all while continuing his work at Pangea Bio. This new role is an exciting step in strengthening Pangea’s presence in the Middle East, fostering new collaborations, and accelerating scientific breakthroughs in AI-driven drug discovery. A huge congratulations to Andreas on this new role! We look forward to seeing the impact of his work and the new opportunities this will bring as the next chapter in our journey at Pangea to develop transformative medicines for neurological and neuropsychiatric disorders. #PangeaBio #AI #DrugDiscovery #Innovation #AbuDhabi #KhalifaUniversity #DrugDevelopment

We’re excited to share our team’s paper on "SimMS: A GPU-Accelerated Cosine Similarity implementation for Tandem Mass Spectrometry" that has been published in the latest issue of Bioinformatics. In this work, we explore how GPU acceleration is transforming computational metabolomics, enabling unprecedented speed and efficiency in data analysis. At Pangea Bio, we use untargeted mass spectrometry metabolomics to identify as many small molecules—or metabolites—as possible from a complex biological sample, such as a plant extract. This is normally time-consuming, involving a large-scale comparison of the fragmentation pattern of a mass spectrum against a database containing known spectra. By leveraging our cutting-edge GPU-accelerated cosine similarity implementation for Tandem Mass Spectrometry (MS) at Pangea Bio, we are reducing compute time by 1700x, thereby dramatically speeding up dereplication and allowing us to efficiently filter out known compounds and focus on discovering novel treatments for neurological and neuropsychiatric disorders. This is pushing the boundaries of what is possible in biological research, making it significantly more efficient. Big #kudos to our team and collaborators for this groundbreaking work! Jui-Hung Yuan Kamen Petrov Vijay I. Lila Khederlarian Niklas Leuchtenmuller Sona Chandra Andreas Bender Yoann Gloaguen Tornike Onoprishvili Aurelien Duarte For those interested in the cutting edge of this technology, be sure to check out our blog post: https://lnkd.in/ern23kBU or read the full article here: https://lnkd.in/en38RW-h #PangeaBio #Metabolomics #GPUComputing #Bioinformatics #AIinScience #AI #DrugDiscovery #DrugDevelopment

Our Co-Founder Manon Veraart and CSO Alleyn Plowright will be at #BioNeuroscience in Amsterdam from February 25-27. Email us at info@pangeabio.com if you are also attending and would like to meet up. We are looking forward to many great conversations! #PangeaBio #Neuroscience #Biotech #CNS #DrugDiscovery #DrugDevelopment #AI #Amsterdam

Our President AI, Sona Chandra, will speak at the Air Street Capital AI meetup at 5.30pm CET today! Request your invite here: https://lu.ma/berlinai #PangeaBio #Berlin #techevents #AI #aimeetup #DrugDiscovery #Biotech

We will be at the J.P. Morgan Healthcare conference in San Francisco next week. If you are also attending and would like to meet the team around Sona Chandra, Piers Morgan, Alleyn Plowright, John Boghossian and Lars Christian Wilde, contact us at info@pangeabio.com. Looking forward to seeing you in #SanFrancisco! #JPMorganConference #JPM25 #Healthcare #Biotech #LifeSciences #Pharma #DrugDiscovery #AI #PangeaBio

We are hiring! We are seeking a highly motivated and experienced Strategy & Operations Manager to join our AI team and drive the management and execution of internal and external projects while contributing to research efforts and supporting strategic decision-making. The candidate will play a key role in supporting execution of key strategic partnerships as well as shaping our platform and business development strategy. Click here to learn more and apply: https://lnkd.in/enGcD46m #PangeaBio #Jobs #Startup #AI #DrugDiscovery #Biotech #Entrepreneurship

Our Co-founder and Executive Director R&D Thomas Pfeiffer will present our work with OT-003, a potential novel small-molecule therapeutic targeting cognitive and negative symptoms associated with Schizophrenia at #ACNP2024 in Phoenix today. Please get in touch if you would like to meet or just visit Thomas at our poster. #Schizophrenia #biotech #drugdevelopment #PangeaBio #Neuropsychiatry #Neuroplasticity

Our CITO, Professor Andreas Bender, will give a presentation on Artificial Intelligence in Drug Discovery at the pharmaceutical conference, CPHI, in Riyadh, Saudi Arabia, on 11 December 2024. This talk coincides with the expansion plans of Pangea Bio into the MENA region and our aims to build both research and business links in Saudia Arabia, the UAE, and beyond. Get in touch at info@pangeabio.com if you are also attending and would like to meet. For more information please see https://lnkd.in/g67VB2fW #PangeaBio #Startup #DrugDevelopment #DrugDiscovery #AI #Biotech #Innovation

Starting today, we will be attending #ACNP2024, the Annual American College of Neuropsychiatry Meeting, in Phoenix, Arizona US, from 8-11th December. This is a fantastic opportunity to engage with leaders, collaborators and investors in the field and discuss the latest progress in neuropsychiatric research and drug development. We can’t wait for the meeting to get started. If you’re attending and would like to connect with our Co-founder and Executive Director R&D Thomas Pfeiffer, please don’t hesitate to reach out or go and see him directly. Thomas will present our work with OT-003, a potential novel small-molecule therapeutic targeting cognitive and negative symptoms associated with Schizophrenia on Tuesday. #ACNP2024 #PangeaBio #DrugDevelopment #Schizophrenia #BrainHealth #Neuropsychiatry #Neuroplasticity